Clinical Innovations

Clinical Innovations, Inc. Will be Participating in the Phase 3 Study DEFEND - DEFEND Testing Otelixizumab in New-Onset, Type 1 Diabetes Mellitus

Clinical Innovations, Inc. announced today that it is now recruiting for DEFEND, a Phase 3 study enrolling patients with newly diagnosed autoimmune type 1 diabetes in Costa Mesa, Riverside and Santa Ana. In DEFEND (Durable Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) the... - July 15, 2009